Target intelligence / Profile preview

Vaginal epithelial surface and local microbiota niche

Molecular classification
Other (Biological niche/Microenvironment)
01

Overview

The vaginal epithelial surface and local microbiota niche constitute a specialized microenvironment critical for maintaining reproductive health and preventing infection (Amabebe & Anumba, 2018, Front Med). The non-keratinized stratified squamous epithelium serves as a physical barrier and an active immunological site, while the resident microbiota—predominantly Lactobacillus species—maintains a low pH (typically <4.5) through the fermentation of glycogen-derived products into lactic acid (Ravel et al., 2011, PNAS; O'Hanlon et al., 2013, PLoS ONE). This acidic environment, supplemented by the secretion of antimicrobial peptides and hydrogen peroxide, provides a robust defense against urogenital pathogens and sexually transmitted infections (STIs). Dysbiosis within this niche, such as the depletion of lactobacilli and overgrowth of anaerobes seen in bacterial vaginosis, is associated with increased risks of HIV acquisition, pelvic inflammatory disease, and preterm birth (Coudray & Madhivanan, 2020, BMC Womens Health). Pharmacological and biotherapeutic strategies targeting this niche, such as the use of live biotherapeutic products like Lactin-V, aim to eradicate pathogens, restore the protective microbial flora, or reinforce the epithelial barrier to maintain local homeostasis (Cohen et al., 2020, NEJM).

Other names
Vaginal microbiomeVaginal mucosaVaginal microenvironmentVaginal niche
02

Mechanism of action

Restoration of microbial homeostasis, acidification of the vaginal environment, and competitive exclusion of pathogens (Cohen et al., 2020, NEJM; O'Hanlon et al., 2013, PLoS ONE).

03

Biological functions

Immune response (Doerflinger et al., 2014, Mucosal Immunol)Barrier functionHomeostasisMetabolic regulation
04

Disease associations

Infection (Bacterial vaginosis, STIs)InflammationPreterm birth (Amabebe & Anumba, 2018, Front Med)
05

Safety considerations

Local irritationVulvovaginal candidiasis (secondary to antibiotic use)Antimicrobial resistance
06

Interacting drugs

Metronidazole

5 more in the full profile.

07

Biomarkers

Vaginal pH (O'Hanlon et al., 2013, PLoS ONE)Nugent score (Coudray & Madhivanan, 2020, BMC Womens Health)Lactobacillus abundance (Ravel et al., 2011, PNAS)Interleukin-1 beta (Amabebe & Anumba, 2018, Front Med)

Beyond the preview

Go deeper on Vaginal epithelial surface and local microbiota niche.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaginal epithelial surface and local microbiota niche.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call